New biologics on the horizon for psoriasis
By Bob Kronmeyer | Reviewed by Bruce Strober, MD, PhD Two biologics in late-stage clinical development are a welcome addition to the armamentarium for treating moderate-to-severe plaque psoriasis: bimekizumab (UCB) and mirikizumab (Eli Lilly and Company). Bimekizumab “Bimekizumab has a novel mechanism of action,” Bruce Strober, MD, PhD, a Clinical Professor of Dermatology at Yale […]